Enasidenib, acting both as a substrate and inhibitor of UGT1A1, is associated with hyperbilirubinemia due to off-target inhibition of the UGT1A1 enzyme (14% overall; 8% grade 3–4) (DiNardo et al., 2023). This evidence concerns the gene UGT1A1 and Hyperbilirubinemia.